Those randomized to panitumumab plus oxaliplatin and bevacizumab (Avastin) had a mean progression-free survival of 9.5 months compared with 11 months in the oxaliplatin/bevacizumab arm.
Panitumumab, a fully human monoclonal antibody that targets EGFr, is approved for monotherapy for chemotherapy-refractory metastatic colon cancer.
There are several tests for colon cancer that enable your doctor to find and diagnose colon cancer before it spreads, including colonoscopy.
Post a Comment to "Vectibix Fails in Treating Metastatic Colon Cancer"
To reply to this message, enter your reply in the box labeled "Message", hit "Post Message."Berger & Lagnese, LLC
310 Grant Street
Suite 720
Pittsburgh, PA 15219
Phone: (412) 471-4300
Fax: (412) 471-3116
Toll Free: (800) 350-6161
Get Directions